PT3599237T - Composição farmcêutica de eliglustat como inibidor de glicosilceramida-sintase para o tratamento de doença de gaucher compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente - Google Patents
Composição farmcêutica de eliglustat como inibidor de glicosilceramida-sintase para o tratamento de doença de gaucher compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doenteInfo
- Publication number
- PT3599237T PT3599237T PT191827328T PT19182732T PT3599237T PT 3599237 T PT3599237 T PT 3599237T PT 191827328 T PT191827328 T PT 191827328T PT 19182732 T PT19182732 T PT 19182732T PT 3599237 T PT3599237 T PT 3599237T
- Authority
- PT
- Portugal
- Prior art keywords
- eliglustat
- metabolism
- disease
- patient
- adjusting
- Prior art date
Links
- 208000015872 Gaucher disease Diseases 0.000 title 1
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 title 1
- FJZZPCZKBUKGGU-AUSIDOKSSA-N eliglustat Chemical compound C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 FJZZPCZKBUKGGU-AUSIDOKSSA-N 0.000 title 1
- 229960002856 eliglustat Drugs 0.000 title 1
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3599237T true PT3599237T (pt) | 2021-04-28 |
Family
ID=43431870
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT161751177T PT3133070T (pt) | 2009-11-27 | 2010-11-24 | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
| PT141646505T PT2796457T (pt) | 2009-11-27 | 2010-11-24 | Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação |
| PT107852899T PT2504332E (pt) | 2009-11-27 | 2010-11-24 | Uma forma amorfa e uma forma cristalina de hemitartrato de genz 112638 como inibidor da glucosilceramida-sintase |
| PT191827328T PT3599237T (pt) | 2009-11-27 | 2010-11-24 | Composição farmcêutica de eliglustat como inibidor de glicosilceramida-sintase para o tratamento de doença de gaucher compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT161751177T PT3133070T (pt) | 2009-11-27 | 2010-11-24 | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
| PT141646505T PT2796457T (pt) | 2009-11-27 | 2010-11-24 | Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação |
| PT107852899T PT2504332E (pt) | 2009-11-27 | 2010-11-24 | Uma forma amorfa e uma forma cristalina de hemitartrato de genz 112638 como inibidor da glucosilceramida-sintase |
Country Status (41)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| SI3133070T1 (sl) | 2009-11-27 | 2019-11-29 | Genzyme Corp | Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta |
| JP6175431B2 (ja) * | 2011-06-20 | 2017-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法 |
| WO2013036875A1 (en) | 2011-09-07 | 2013-03-14 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| PT2854910T (pt) | 2012-06-01 | 2020-05-06 | Yeda Res & Dev | Níveis de ceramida no tratamento e prevenção de infeções |
| HUE046113T2 (hu) | 2013-03-14 | 2020-02-28 | Icahn School Med Mount Sinai | Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai |
| EP3912977A1 (en) * | 2013-09-20 | 2021-11-24 | BioMarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| CA2954030A1 (en) * | 2014-07-03 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| EP3283483B1 (en) | 2015-04-14 | 2018-12-19 | Sandoz AG | Crystalline eliglustat hydrochloride |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| AU2016357720A1 (en) | 2015-11-18 | 2018-07-05 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) * | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| ZA201803719B (en) | 2017-06-05 | 2019-04-24 | Cipla Ltd | Stable solid dispersions of eliglustat hemitartrate |
| SG11201911859QA (en) * | 2017-06-16 | 2020-01-30 | Beta Pharma Inc | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| US20200222310A1 (en) * | 2017-08-08 | 2020-07-16 | Kashiv Biosciences, Llc | Pharmaceutical composition comprising eliglustat |
| US20200197366A1 (en) * | 2017-08-08 | 2020-06-25 | Kashiv Biosciences, Llc | Pharmaceutical composition comprising eliglustat |
| US10888544B2 (en) | 2017-12-15 | 2021-01-12 | Genzyme Corporation | Methods for treating Gaucher disease |
| US20200316025A1 (en) * | 2017-12-20 | 2020-10-08 | Aizant Drug Research Solutions Private Limited. | Stable amorphous eliglustat premix and process for the preparation thereof |
| WO2019211778A2 (en) * | 2018-05-02 | 2019-11-07 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| CA3101097A1 (en) * | 2018-05-27 | 2019-12-05 | Bioasis Technologies Inc. | Treatment of gaucher disease |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| CN116120274A (zh) | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| CN1128951A (zh) | 1993-08-13 | 1996-08-14 | 生化学工业株式会社 | 治疗神经元疾病的药物 |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| ATE195944T1 (de) | 1994-02-02 | 2000-09-15 | Liposome Co Inc | Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung |
| AU698833B2 (en) | 1994-06-10 | 1998-11-12 | Seikagaku Corporation | 2-acylaminopropanol compound and medical composition |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6890949B1 (en) | 1999-07-09 | 2005-05-10 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| EP1098642B1 (en) | 1998-07-27 | 2007-04-04 | Johns Hopkins University | Diamino-propanol-compounds for treating ischemia |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| EP1196406A1 (en) * | 1999-07-09 | 2002-04-17 | The Regents of the University of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US6977723B2 (en) | 2000-01-07 | 2005-12-20 | Transform Pharmaceuticals, Inc. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| US20020048610A1 (en) * | 2000-01-07 | 2002-04-25 | Cima Michael J. | High-throughput formation, identification, and analysis of diverse solid-forms |
| DE60125429T2 (de) | 2000-04-24 | 2007-09-27 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrat solvat |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| WO2002062777A2 (en) | 2001-01-10 | 2002-08-15 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| MXPA03006294A (es) * | 2001-01-18 | 2003-09-16 | Merck Patent Gmbh | Proteinas de fusion disfuncionales con actividad glucocerebrosidasa. |
| ATE554082T1 (de) | 2001-07-16 | 2012-05-15 | Genzyme Corp | N-acetylsphingosin glukosyltransferase inhibitor |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| EP1889839B1 (en) | 2001-08-08 | 2013-11-06 | Tobira Therapeutics, Inc. | Bicyclic compound, production and use as HIV inhibitors |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| JP2005535665A (ja) | 2002-07-09 | 2005-11-24 | ザ スクリプス リサーチ インスティテュート | 虚血および再灌流損傷を防止する方法 |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| WO2005070938A1 (en) * | 2004-01-27 | 2005-08-04 | Synthon B.V. | Stable salts of olanzapine |
| CA2582022C (en) | 2004-09-30 | 2021-05-18 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
| CA2584246C (en) | 2004-10-13 | 2011-08-09 | Pharmacia & Upjohn Company Llc | Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide |
| US8003617B2 (en) * | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| US20070088082A1 (en) * | 2005-09-28 | 2007-04-19 | Judith Aronhime | Polymorphic forms of ladostigil tartrate |
| EP1948655A1 (en) * | 2005-10-03 | 2008-07-30 | Mallinckrodt, Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| PT2032134E (pt) * | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| MX2009010557A (es) * | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| WO2008134628A2 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2594565B1 (en) | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| US20090307180A1 (en) | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| WO2009117150A2 (en) * | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| SI3133070T1 (sl) | 2009-11-27 | 2019-11-29 | Genzyme Corp | Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta |
| BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
| PE20121742A1 (es) | 2009-11-27 | 2012-12-13 | Adverio Pharma Gmbh | PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO |
| IN2014DN00145A (pt) | 2011-06-21 | 2015-05-22 | Novartis Ag | |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko active Search and Examination
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active IP Right Cessation
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en active Application Filing
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active IP Right Cessation
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Application Discontinuation
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en active Active
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active IP Right Grant
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
- 2012-12-14 HK HK15103822.1A patent/HK1203485A1/zh unknown
- 2012-12-14 HK HK12112977.8A patent/HK1172031A1/xx unknown
-
2014
- 2014-08-18 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
- 2015-11-02 PH PH12015502514A patent/PH12015502514A1/en unknown
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en active Pending
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es unknown
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es unknown
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US20230172903A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3599237T (pt) | Composição farmcêutica de eliglustat como inibidor de glicosilceramida-sintase para o tratamento de doença de gaucher compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente | |
| HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
| ZA201100034B (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| EP2151435A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL202083A0 (en) | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system | |
| IL202515A (en) | Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases | |
| EP2510916A4 (en) | ANTISEPTIC PHARMACEUTICAL COMPOSITION USEFUL FOR ORAL HYGIENE AND THE TREATMENT OF BUCCAL DISEASES OF MICROBIAL ORIGIN | |
| HK1150390A1 (en) | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases | |
| EP2306824A4 (en) | IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| HK1142823A1 (en) | Formulations for the oral administration of therapeutic agents and related methods | |
| MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
| HK1176548A1 (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease mgbg | |
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
| EP2236137A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FAT TEMPERATURE DISEASES | |
| EP2175722A4 (en) | PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS | |
| EP2231148A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | |
| IL217519A (en) | Derivatives of tazarotene, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of skin diseases | |
| PL385972A1 (pl) | Kompozycja farmaceutyczna do leczenia chorób przyzębia | |
| HUP0800498A2 (en) | Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level | |
| IL206464A0 (en) | Pharmaceutical composition, use of 2-imminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases | |
| IL194066A0 (en) | Therapeutic composition for treatment of tinnitus | |
| EP2517704A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME | |
| IL209804A0 (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| HU0800083D0 (en) | Pharmaceutical compositions for the treatment and prevention of tumorous diseases |